Kornimate/medical-research-clean huggingface dataset:
cognitive trance, hypnosis and meditation in oncology

Conditions: Cancer; Distress, Emotional; Pain; Fatigue; Sleep Disturbance; Cognitive Impairment

Summary: patients with cancer often suffer from a symptom cluster, including pain, fatigue, sleep difficulties, emotional distress and cognitive impairments. in oncology settings, there is a growing interest in "mind-body" intervention, to relieve them in a non-pharmacological way. hypnosis and meditation are two modified state of consciousness shown to positively this symptom cluster. cognitive trance is also a modified state of consciousness, but is induced by body movements and/or vocalizations. subjective reports of experts in cognitive trance showed a modification of self, emotion regulation, pain perception, attention and concentration. however, we still need to develop studies to better characterise this particular state of consciousness and its clinical applications. our randomized-controlled trial aims at comparing both interventions in terms of (1) benefits on cancer patients' quality of life (pain, fatigue, sleep, distress, cognitive impairments), (2) phenomenological/subjective experiences and neurophysiological correlates, and (3) mechanisms involved in patients' responsiveness, based on the biopsychosocial model of hypnosis.


Eligibility criteria:
inclusion criteria: * ≥18 years old * no neurological/psychiatric disorders/history of alcohol or drug abuse * no current and regular practice of hypnosis, meditation or cognitive trance * diagnosis of cancer (all localisations accepted except brain tumours to avoid any effect on eeg data and cognitive impairments) * active treatments (surgery, chemotherapy, radiotherapy) finished for less than a year. * score of at least 4/10 for one of these four symptoms at baseline: pain, fatigue, sleep difficulties, emotional distress. exclusion criteria: * \< 18 year old * no cancer diagnosis * neurological or psychiatric disorder * brain tumour ou other tumour with brain metastases * active treatments still ongoing or finished for more than a year * no baseline symptom at 4/10

Keywords: hypnosis cognitive trance meditation cancer oncology quality of life neurophysiology phenomenology
a study to evaluate the efficacy of an oral medication in the treatment and prevention of digital ulcers in patients with systemic sclerosis (scleroderma).

Conditions: n Ulcer; Scleroderma, Systemic

Summary: this is a research study of an investigational drug called ambrisentan (letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.

ambrisentan is an endothelin blocker approved for the treatment of pulmonary arterial hypertension. patients with systemic sclerosis can have damage to their blood vessels, resulting in increased levels of endothelin in their bloodstream that then causes decreased blood flow to the digits. this can result in very painful digital ulcers. we hope to learn whether blocking the action of endothelin with ambrisentan will be helpful in the treatment and prevention of digital ulcers in patients with systemic sclerosis. this therapy is not approved for the treatment of systemic sclerosis, but this study will help us learn whether ambrisentan is safe and effective in the treatment and prevention of digital ulcers in patients with systemic sclerosis.

Eligibility criteria:
inclusion criteria: * diagnosis of limited or diffuse systemic sclerosis (ssc) according to american college of rheumatology or leroy criteria * age greater than 18 years of age * at least one digital ulcer located on the volar or lateral surface at or distal to the proximal interphalangeal joints * at least one new du that developed within 12 weeks prior to screening * vasodilator therapies, including calcium channel blockers, alpha-1-antagonists, ace-inhibitors, nitroglycerin, and angiotensin receptor blockers, are permitted as long as the doses are stable for 2 weeks prior to screening and throughout the study * treatment with omeprazole or other proton pump inhibitors must be stable for 2 weeks prior to screening and throughout the study exclusion criteria: * patients with pulmonary arterial hypertension, nyha class iii or iv * patients who are hemodynamically unstable, or have acute renal, cardiac or pulmonary failure * concurrent malignancy except non-melanoma skin cancers * patients who have required systemic antibiotics for infected digital ulcers within 2 weeks of screening * patients receiving phosphodiesterase-5 inhibitors, endothelin receptor antagonists, or prostanoids within 4 weeks of screening * patients receiving cyclosporine within 6 weeks of screening * patients who have participated in any investigational study within 30 days of screening * pregnant or nursing women * patients with a history of drug or alcohol abuse within 6 months of screening * history of hepatitis b, hepatitis c, or hiv infection * any medical condition that, in the opinion of the investigator, might interfere with the subject's participation in the study or poses an added risk for the subject * inability to comply with study and follow-up procedures * transaminase elevation \> 3x the upper limit of normal at screening * hemoglobin less than 8.5 g/dl * platelet count less than 100 x 109/l * white blood cell count less than 3.0 x 109/l * serum creatinine less than 2.0 mg/dl
chronic pain after inguinal herniorrhaphy

Conditions: Inguinal Hernia

Summary: the purpose of this study is to determine whether laparoscopic inguinal hernia repair leads to a lower incidence of chronic pain compared to open herniorrhaphy.


Eligibility criteria:
inclusion criteria: * primary inguinal hernia exclusion criteria: * history of severe mental illness or chronic pain elsewhere
effects of quercetin on cardiometabolic outcomes

Conditions: Cardiometabolic Syndrome

Summary: cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. it has been postulated that quercetin may be beneficial in improving cardiometabolic outcomes. however, to date, no research has explored this using a placebo randomized intervention.


Eligibility criteria:
inclusion criteria: * healthy * between 18 \& 65 years * non-smoker * bmi \< 30 * able to give informed consent exclusion criteria: * pregnancy * diabetes or any other metabolic/ uncontrolled hypertensive conditions * food allergies to quercetin * habitual consumption of quercetin * not regularly taking medication or antioxidant supplements
the impact of the social factors and rehabilitation program to address the implications on kidney failure in hail

Conditions: Chronic Renal Disease

Summary: the aims of our study to evaluate the effect of social factors and medical rehabilitation program on kidney function and quality of life among chronic kidney disease patients.

1. this study aims to evaluate the effect of social factors and medical rehabilitation program on kidney function and quality of life among chronic kidney disease patients. 2. identify the health problems facing patients with kidney failure in hail region. 3. detect the reality of the problems facing patients with kidney failure in hail region and ways to reduce them. 4. identify the family, psychological, economic and social problems facing patients with kidney failure in hail region.

Eligibility criteria:
inclusion criteria: participants with ckd stages (3 and 4) will be participated in this study, their ages ranged from 40 to 60 years. both sexes will be included. participants should be: saudi persons living in hail city, married, both genders, exclusion criteria: * (1) severe chronic cardiac problems. (2) chronic chest disease. (3) chronic inflammatory orthopedic disorders and rheumatoid arthritis. (4) mental impairments.

Keywords: renal failure patients -saudi community - social program
the diabetic foot ulcer registry

Conditions: Diabetic Foot Ulcer Outcome; Quality of Patient Care

Summary: this is an observational, longitudinal real world registry of diabetic foot ulcers created from electronic health record data obtained in the course of clinical care. data from certified electronic health records transmit data as part of the requirement to share data with a specialty registry under objective 10 of meaningful use of an ehr.

this is an observational, longitudinal real world registry of diabetic foot ulcers created from electronic health record data obtained in the course of clinical care. data from certified electronic health records transmit data as part of the requirement to share data with a specialty registry under objective 10 of meaningful use of an ehr. no secondary data entry are required and all data are obtained via structured language from data entered in the ehr. data from quality measures designed as electronic clinical quality measures (ecqms) standardize the quality of care provided to patients and their clinical outcomes which are risk stratified using the wound healing index (whi). the ecqms enable standardized data collection and the ability to transmit data electronically obviates the possibility of transcription errors. national benchmarking is possible since data are available from thousands of participants across the usa. while an independent irb oversees this project, the data are collected for the purpose of measuring and improving the quality of care delivered to diabetic patients with foot ulcers and understanding their outcomes in relation to level of risk. quality performance is reported as part of pqrs. these functions are exempt from the requirements of informed consent.

Eligibility criteria:
inclusion criteria: * all patients with diabetic foot ulcers seen by the practitioner exclusion criteria: * none

Keywords: diabetic foot ulcer diabetes arterial disease neuropathy amputation qcdr quality measure wound
liposomal irinotecan in combination with oxaliplatin and s-1 versus gemcitabine combined with capecitabine as postoperative adjuvant therapy for pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and s-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.


Eligibility criteria:
inclusion criteria: 1. patients able and willing to provide a written informed consent aged 18-75 years. 2. histologically confirmed resected ductal pancreatic adenocarcinoma (including adenosquamous carcinoma). 3. undergone radical resection and confirmed macroscopic complete resection (r0 and r1). 4. full recovery after surgery; able to start adjuvant treatment within 12 weeks after surgery. 5. eastern cooperative oncology group (ecog) performance status 0-1. 6. the main organs function well. exclusion criteria: 1. patients with other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, pancreatoblastoma, and solid-pseudopapillary tumor. 2. macroscopic incomplete tumor removal (r2 resection). 3. prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma. 4. presence or history of metastatic or locally recurrent pancreatic adenocarcinoma. 5. ca 19-9\> 180 u / ml within 21 days before randomization. 6. the toxicity of previous therapy has not recovered to grade 1 or below. 7. known peripheral neuropathy (ctcae ≥ grade 2). 8. known deficiency of dihydropyrimidine dehydrogenase (dpd) 9. subjects with a confirmed diagnosis of gilbert's syndrome
glycerol block of the trigeminal ganglion in trigeminal neuralgia using a new neuronavigation-based surgical technique

Conditions: Trigeminal Neuralgia; Headache Disorders

Summary: trigeminal neuralgia is one of the strongest pains known to humans. some patients do not have enough effect with the available pharmaceutical treatments and are offered a type of surgery, which involves the injection of glycerol in a nerve structure called trigeminal ganglion. the researchers will do a pilot study on 10 patients with a new surgical technique using neuronavigation. the researchers believe that this new neuronavigation-based system can improve the precision of the technique and reduce the risk for complications.


Eligibility criteria:
inclusion criteria: * informed and written consent * trigeminal neuralgia defined in international classification of headache disorders (ichd)-3 criteria * unsatisfactory effect of pharmacological treatment exclusion criteria: * microvascular decompression is seen as a better alternative * heart or lung disease * any kind of systematic or local disease or illness that may significantly increase the risk of complications for the procedure related to injection * psychiatric illness that hinders participation in the study * known pregnancy or breast feeding * inadequate use of contraceptives * overuse or abuse of opioids * abuse of medications, narcotics or alcohol * anomalies which hinder or impede the used method of injection * allergy or any other hypersensitivity reactions against marcain, lidocaine, xylocain or adrenalin

Keywords: trigeminal ganglion glycerol nerve block
life after breast cancer - impact of a life coach

Conditions: Survivorship; Breast Cancer

Summary: the objectives of our intervention are to 1. ease the transition between cancer treatment and active life, and 2. allow breast cancer survivors to take control of their lives. the primary objective of this study is to: 1) determine whether individual life coaching (i.e., individualized guidance that helps to put resources into action) can significantly improve quality of life and post-traumatic growth among women who have been recently treated with breast cancer. it is hypothesized that: 1. participants who receive both "group coaching sessions" and "individualized coaching sessions" will report greater post-traumatic growth and quality of life, and less fear of cancer recurrence when compared to the breast cancer survivors who received only the group coaching sessions or usual care. 2. participants who receive only the group coaching sessions will report greater post-traumatic growth and quality of life, and lesser fear of cancer recurrence when compared to the participants who receive usual care.


Eligibility criteria:
inclusion criteria: 1. have been diagnosed with stage i, ii, or iii breast cancer; 2. are female breast cancer patients over the age of 18; 3. have completed anti-cancer treatment via surgery and/or chemotherapy and /or radiation therapy at the mcgill university health centre breast clinic; 4. are fluent in written and spoken english or french; 5. are alert and oriented and capable of giving informed consent; 6. have an internet connection at home that supports participation in coaching sessions via videoconferencing (zoom). exclusion criteria: 1. have a recurrence of breast cancer; 2. are diagnosed with a second cancer; 3. are diagnosed with stage iv breast cancer due to their worse prognosis; and 4) have an active psychiatric diagnosis that would render adherence to the study problematic.

Keywords: breast cancer survivorship post-traumatic growth quality of life fear of recurrence randomized controlled trial
closed-loop dbs in parkinson's disease

Conditions: Parkinson Disease

Summary: closed-loop dbs is an emerging neuromodulation pattern in parkinson's disease with dyanmic adjustment of stimulation parameters to patients' disease fluctuations and state of activity. the purpose of this study is to verify the long-term safety and effectiveness of closed-loop dbs. through comparing with open-loop dbs, the study also determine whether closed-loop dbs is more effective than conventional open-loop dbs on pd treatment.


Eligibility criteria:
inclusion criteria: 1. diagnosis of primary parkinson's disease: diagnosis of primary parkinson's disease should meet the diagnostic criteria outlined in the "diagnosis standards for parkinson's disease in china" published in 2016 or the diagnostic criteria for primary parkinson's disease by the international parkinson and movement disorder society (mds) published in 2015. 2. good response to levodopa combination therapy. 3. significant reduction in drug efficacy or significant impact on the patient's quality of life due to prominent motor complications. 4. intolerable adverse reactions to medication affecting its efficacy. 5. presence of uncontrollable tremors despite medication. exclusion criteria: 1. patients who have undergone pallidotomy or other brain surgeries. 2. patients with secondary parkinson syndromes or parkinson plus syndromes. 3. patients with concurrent central nervous system and peripheral nervous system diseases. 4. patients with severe systemic diseases, unstable vital signs, or those who cannot tolerate clinical assessments. 5. patients with severe psychiatric disorders. 6. patients who are unable to provide informed consent due to cognitive or communication impairments or those who refuse to sign the informed consent form.

Keywords: parkinson disease deep brain stimulation closed-loop dbs
hemodialysis access surveillance evaluation study

Conditions: Hemodialysis Access; Thrombosis

Summary: the purpose of the study is to learn if monitoring dialysis access blood flow during dialysis treatment with a transonic machine (an ultrasound technique) will prevent (or reduce) the development of dialysis access thrombosis (clotting). investigators would like to study if monitoring with a specific technique called ultrasound dilution technique can help prevent problems with access when compared to what is the current standard of care for patients.


Eligibility criteria:
inclusion criteria: * chronic hemodialysis patients undergoing dialysis therapy via an upper extremity arteriovenous access (arteriovenous fistula or an arteriovenous graft) will be enrolled to have monthly surveillance flow measurement using transonic system or physical examination of the arteriovenous access by qualified person at least once a month for a period of 2 years. exclusion criteria: * patients requiring surgical intervention on the arteriovenous access. * history of access thrombosis (one or more access thrombosis of the current arteriovenous access). * patients with signs of access infection. * patients with a malignancy. * patients with life expectancy of less than six months. * unable to understand the study. * unable to sign the consent form. * patients with psychiatric disorder. * age less than 18 or greater than 80 years. * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners

Keywords: surveillance
coagulopathy in acute aortic syndrome

Conditions: Coagulopathy

Summary: the existence of aas coagulopathy has been reported, related to blood contact with the walls of the non-endothelialized false lumens. it is likely that endothelial dysfunction generated by vascular lesions may largely contribute to the development of coagulopathy, such as described in trauma-induced coagulopathy. this endotheliopathy of the aas has never been evaluated. the coagulopathy of aas and more specifically the endotheliopathy are poorly described and therefore have no standardized treatment. the main objective of this study is to describe the coagulopathy

acute aortic syndromes (aas) result from an organic lesion of the aortic wall. the various symptoms of aas, mainly the acute chest pain, leads to a breakdown of the intima or the media of the aorta. this syndrome is made of three entities : aortic dissection (da), intra-mural hematoma (him) and penetrating atherosclerotic ulcer (pau). surgery is a complex emergency treatment of choice. patients suffering from these pathologies die mainly from hemorrhagic shock due to haemostasis disorders, which requires massive transfusion. the existence of aas coagulopathy has been reported, related to blood contact with the walls of the non-endothelialized false lumens. it is likely that endothelial dysfunction generated by vascular lesions may largely contribute to the development of coagulopathy, such as described in trauma-induced coagulopathy. this endotheliopathy of the aas has never been evaluated. the coagulopathy of aas and more specifically the endotheliopathy are poorly described and therefore have no standardized treatment. the main objective of this study is to describe the coagulopathy and more specifically the endotheliopathy of aas, in particular assessing coagulation disorders, hyperactivation of fibrinolysis, quantitative or functional platelets disorder and endotheliopathy. the secondary objective is to determine the factors associated with this coagulopathy. this includes 1 / assessment of potential risk factors for coagulopathy, 2 / the prognosis of coagulopathy by assessing the relationship between coagulopathy and transfusion requirements and mortality.

Eligibility criteria:
inclusion criteria: * admitted to hospital via the "sos aorta" network for acute aortic syndrome (aas) suspicion exclusion criteria: * aged \< 18y * pregnant women * no social security

Keywords: coagulopathy acute aortic dissection blood transfusion
liposomal doxorubicin in treating patients with advanced or recurrent endometrial cancer

Conditions: Endometrial Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of liposomal doxorubicin in treating women who have recurrent, stage iii, or stage iv endometrial cancer.

objectives: * determine the antitumor activity and safety of doxorubicin hcl liposome in patients with advanced or recurrent endometrial cancer. * determine the response rate, response duration, and overall survival of these patients treated with this regimen. outline: patients receive doxorubicin hcl liposome iv over 1 hour. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years and then every 6 months for 3 years. projected accrual: a total of 19-51 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed stage iii, iv, or recurrent endometrial carcinoma for which curative radiotherapy or surgery is not an option * bidimensionally measurable disease * irradiated field as only site allowed if evidence of progression since radiotherapy patient characteristics: age: * not specified performance status: * gog 0-2 life expectancy: * not specified hematopoietic: * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 1.5 times upper limit of normal (uln) * sgot no greater than 3 times uln * alkaline phosphatase no greater than 3 times uln renal: * creatinine no greater than 1.5 times uln cardiovascular: * lvef normal by cardiac echocardiogram or muga other: * no concurrent active infection * no prior or concurrent malignancy within past 5 years except nonmelanoma skin cancer prior concurrent therapy: biologic therapy: * not specified chemotherapy: * prior chemotherapy as radiosensitizer allowed * no prior chemotherapy for advanced or metastatic disease * no other concurrent chemotherapy endocrine therapy: * not specified radiotherapy: * see disease characteristics * recovered from prior radiotherapy surgery: * see disease characteristics * recovered from prior surgery other: * no prior therapy that would preclude study * no other concurrent antineoplastic agents * no other concurrent investigational agents

Keywords: stage iii endometrial carcinoma stage iv endometrial carcinoma recurrent endometrial carcinoma